Superiority of deucravacitinib was demonstrated on both co-primary endpoints and multiple key secondary endpoints in the POETYK PSO-1 trial The overall safety profile of deucravacitinib in this study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback